RLMD · Relmada Therapeutics Inc

-

Please sign in to comment on RLMD

1 Comment

Admin

4 years ago

Relmada Therapeutics, Inc is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Relmada Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 98.7% to $-59K since the same quarter in the previous year.

Finally, its free cash flow fell by 78.6% to $-7M since the same quarter in the previous year.

Based on the above factors, Relmada Therapeutics, Inc gets an overall score of 2/5.

Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CurrencyCode	USD
ISIN	US75955J4022

Market Cap	23M
PE Ratio	None
Target Price	0.8667
Beta	0.41
Dividend Yield	None

ABOUT

Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of NDV-01, a novel controlled-release intravesical formulation of gemcitabine and docetaxel which is in Phase 2 clinical trial in patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a novel neurosteroid epimer of allopregnanolone for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity. The company is headquartered in Coral Gables, Florida.

RLMD · Relmada Therapeutics Inc

-

Relmada Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Relmada Therapeutics Inc using a moving average strategy